New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population

SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA.2In another post-hoc analysis of DISCOVER-2, a diverse population of bio-naïve, TREMFYA-treated patients sustained several PsA disease control endpoints through two years, regardless of their baseline characteristicsd or dosing regimen,e including minimal disease activity (MDA) response,f skin clearance (IGA 0)g and resolution of dactylitis.3,h“Active psoriatic arthritis is a chronic, lifelong condition that can be progressive for many patients, leading to extensive and permanent joint damage,” said Philip J. Mease, M.D.,i Swedish Medical Center/Providence St. Joseph Health and University of Washington in Seattle, Washington. “The data derived from TREMFYA-treated patients in the DISCOVER program give us more tools to evaluate treatment plan options that may help facilitate long-term relief as we work toward the ultimate goal of disease remission."&n...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news